HER3-targeted antibody-drug conjugate shows promise for treatment-resistant solid tumors

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer

The call to Fire Captain Brian Buchanan and his crew came at midnight. Northern California firefighters were urgently needed to help fight the wildfires that were devouring big swaths of Los Angeles.

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Approximately 21 years ago, I had the privilege of working and helping to pass Proposition 71, which authorized $3 billion dollars in state bonds to fund stem cell research in California.

February 20, 2026

Vol.52 No.07

By Stephen J. Forman

Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

Autoimmune and inflammatory diseases arise when the immune system becomes misdirected, attacking the tissues it is meant to protect.

February 20, 2026

Vol.52 No.07

By Christine Brown and Enrique Montero

In Brief

CPRIT approves more than $15M in new funding for cancer research and recruitment

The governing board of the Cancer Prevention and Research Institute of Texas met in Austin and approved more than $15 million in CPRIT Scholar recruitment grants to bring five new cancer scientists to four Texas research institutions.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Findings from Cincinnati Children’s study could make immune checkpoint inhibitors safer

Experts at Cincinnati Children’s report proof-of-concept results that may sharply reduce the risk of a lethal side effect that has negatively impacted the use of revolutionary cancer immunotherapies.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior.

February 20, 2026

Vol.52 No.07

HER3-targeted antibody-drug conjugate shows promise for treatment-resistant solid tumors

YOU MAY BE INTERESTED IN

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

CPRIT approves more than $15M in new funding for cancer research and recruitment

Findings from Cincinnati Children’s study could make immune checkpoint inhibitors safer

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login

HER3-targeted antibody-drug conjugate shows promise for treatment-resistant solid tumors

YOU MAY BE INTERESTED IN

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risksRespirators (restricted by federal regulation) may or may not be the answer

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

CPRIT approves more than $15M in new funding for cancer research and recruitment

Findings from Cincinnati Children’s study could make immune checkpoint inhibitors safer

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

Never miss an issue!

Login

A year after LA wildfires, early data reinforce anxieties over firefighters’ cancer risks
Respirators (restricted by federal regulation) may or may not be the answer